Countstar


Japanese professor shinya yamanaka won the first US patent in Japan for developing iPS technology

Shinya yamanaka, a professor at Kyoto university, has received a 20-year patent in the United States for his induced pluripotent stem cell (iPS) culture technique, the university announced on Tuesday. It is the first U.S. patent for a Japanese technology.

Induced pluripotent stem cells (ipscs) are item cells derived from animal somatic cells treated with inducible factors. It has similar functions to embryonic stem cells and can develop into tissues and organs. Meanwhile, it avoids the ethical and legal barriers faced by embryonic stem cell research and has a very broad prospect in the medical field.

"Obtaining a patent is important for conducting research and development with the peace of mind" Mr Yamanaka told a news conference. Research will continue in the future and hopefully contribute to clinical treatment.

Japanese media believe that the US patent, which is at the forefront of regenerative medicine, will further promote the practical research of induced pluripotent stem cell technology.

Kyoto university has applied for six patents in the United States for the basic technique of cultivating induced pluripotent stem cells, which involves the implantation of three genes into human and other animal cells, or a technology that using two genes and a protein that promotes cell proliferation to culture induced pluripotent stem cells.

So far, Kyoto university's induced pluripotent stem cell culture technology has also been patented in Europe, South Africa and Russia.
Related News
  • Stem cell therapy may cure Parkinson's diseaseMay 16, 2019

    Stem cell therapy may cure Parkinson's disease

    Researchers used stem cells from human embryos to successfully treat Parkinson's disease in mice and rats. This is a key step in finding similar treatments for humans.In a study published on this sund...view
  • Stem Cell Therapy: Reversing DiabetesMarch 25, 2019

    Stem Cell Therapy: Reversing Diabetes

    Type I diabetes is caused by the body's autoimmune system attacking pancreatic islet beta cells, requiring daily insulin injections to regulate blood sugar levels. A new method, published in BMC Medic...view
  • Countstar Exhibited 2017 International Biotherapy ConferenceApril 8, 2018

    Countstar Exhibited 2017 International Biotherapy Conference

    In the past 10 years, Tumor immunotherapy technology has been a major development, and gradually applied to clinical trials. As one of the hopes of the ultimate capture of the tumor, immunotherapy has...view